Q-omics provides the consensus-scored MIR601 profile across patient tissues and cancer cell-line models. MIR601 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR601 is differentially expressed in 7, with the highest sampling consensus in READ. Additionally, MIR601 RNA expression shows 10,152 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, READ, and THYM as cancer lineages where MIR601 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR601 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR601 survival associations across molecular data types. MIR601 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR601 RNA expression–survival associations across cancer types. High MIR601 expression shows unfavorable associations in BLCA, LUSC, READ, MESO and ACC, but favorable associations in UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR601 RNA expression.
This table summarizes MIR601 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR601. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR601 shows lower tumor expression in PAAD and higher tumor expression in READ, BRCA, HNSC, KICH and LUAD. The READ box plot shows higher MIR601 RNA expression in tumor versus normal tissue (log2 FC = +0.860, t-test p < 0.001).
This table shows molecular features associated with MIR601 in patient tissues and cancer cell lines. In patient samples, MIR601 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
